Introduction to
FFPE Samples with Orthogonally Validated NGS Results
FFPE Samples with Confirmed and Orthogonally Validated NGS Findings
FFPE specimens with NGS findings confirmed through an independent analytical method can provide a higher-confidence reference set for molecular research. Orthogonal validation may involve techniques such as PCR, digital PCR, Sanger sequencing, FISH, immunohistochemistry or another suitable methodology depending on the alteration being investigated. These independently confirmed results are particularly valuable when researchers require greater confidence that a detected mutation, amplification, fusion or other genomic event is truly present in the specimen.
Such samples can support assay development, analytical verification and technology benchmarking. For companies developing new sequencing assays or molecular diagnostic platforms, orthogonally validated FFPE specimens can function as biologically relevant reference materials. They can also help researchers evaluate analytical sensitivity, specificity and concordance across different testing technologies while working with clinically realistic tumor material.
High-Confidence FFPE Reference Samples for NGS Assay Validation
Molecular assay developers need reference specimens representing clinically relevant genomic alterations at different frequencies and biological backgrounds. FFPE samples with validated NGS findings can provide these reference points while preserving the complexity of real tumor tissue. Unlike synthetic controls, tissue-based samples contain variable tumor content, stromal components, necrosis and other characteristics encountered during routine laboratory testing.
Â
Orthogonal confirmation of key alterations increases confidence in the expected molecular status of the sample. Such materials may be useful for evaluating extraction methods, library preparation, sequencing pipelines, variant-calling algorithms and reporting workflows. Researchers can also construct mutation-positive and mutation-negative cohorts for analytical studies. Carefully selected FFPE reference specimens therefore help bridge the gap between technical assay development and the biological complexity that diagnostic technologies must manage in real-world oncology samples.
Validated Mutation-Positive FFPE Samples for Biomarker Studies
Biomarker studies frequently require tumor samples containing specific genomic alterations such as mutations, amplifications, deletions or fusions. When these alterations have been detected by NGS and confirmed using an independent method, the sample can provide stronger evidence for downstream research. Validated mutation-positive FFPE specimens may be used to investigate relationships between genomic alterations, histological features, protein expression and therapeutic response.
They can also support development of targeted PCR assays, companion diagnostics, digital pathology algorithms or molecular stratification models. Researchers may select specimens based on cancer indication, alteration type, variant allele frequency, tumor percentage or additional clinical characteristics where available. This targeted approach can reduce unnecessary screening and allow teams to focus experimental resources on samples that already meet key molecular criteria.
Orthogonally Characterized FFPE Material for Precision Oncology Development
Precision-oncology technologies depend on reliable molecular ground truth. FFPE specimens characterized using both NGS and an independent validation method can provide robust datasets for the development of diagnostics, software and therapeutic research tools. These samples can be incorporated into studies evaluating concordance between sequencing panels, validating new analytical pipelines or training artificial-intelligence systems that predict molecular alterations from pathology images. Orthogonal testing can provide additional confidence in key biomarker labels used during model development and performance evaluation. When combined with pathology review, clinical annotation and digital slide data, validated FFPE specimens become especially valuable for multimodal research. This type of high-confidence tissue resource can support pharmaceutical companies, diagnostic developers, biotech firms and academic researchers working to translate genomic discoveries into more reliable precision-medicine technologies.
General Questions
Frequent Asked Questions!!
FFPE blocks for genomics are formalin-fixed, paraffin-embedded tissue samples used for DNA, RNA, and biomarker analysis. They are widely used in cancer genomics, molecular pathology, translational research, and retrospective studies.
FFPE tissue blocks are valuable because they preserve tissue architecture and molecular material for long-term storage. Researchers can use them for sequencing, mutation analysis, biomarker discovery, and validation studies.
Yes. DNA can be extracted from FFPE blocks using validated extraction kits and optimized laboratory protocols. DNA quality depends on fixation time, block age, tissue type, tumor content, and storage conditions.
Yes. RNA can be extracted from FFPE tissue, although it is often fragmented because of formalin fixation. Specialized FFPE RNA extraction methods can provide material suitable for targeted RNA sequencing, gene expression studies, and fusion analysis.
Yes. High-quality FFPE blocks are commonly used for next-generation sequencing, including targeted sequencing panels, whole-exome sequencing, RNA sequencing, and selected whole-genome applications.
Tumor content requirements depend on the study design and testing method. Many molecular and NGS studies require at least 20% tumor content, while some projects may require 30%, 50%, or higher tumor percentage. Pathologist review can be performed to confirm tumor content before shipment
FFPE blocks can support mutation testing, copy number analysis, gene fusion detection, microsatellite instability testing, tumor mutational burden analysis, methylation studies, and targeted DNA or RNA sequencing.
Yes. FFPE cancer tissue blocks are extensively used to study genomic alterations in lung, breast, colorectal, prostate, ovarian, pancreatic, liver, kidney, and other tumor types.
Researchers can purchase FFPE blocks from qualified biospecimen suppliers, biobanks, pathology laboratories, hospitals, and research networks that provide ethically sourced and clinically annotated human tissue samples.
Researchers should confirm diagnosis, tissue type, tumor percentage, necrosis percentage, fixation details, block age, specimen size, available clinical data, pathology review, consent status, and intended research-use permissions.
Yes. Clinically annotated FFPE blocks may include donor age, sex, diagnosis, grade, stage, TNM classification, treatment history, pathology report, mutation status, and clinical outcome data.